10/607,829

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:52:23 ON 20 DEC 2004

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'BIOSIS' ENTERED AT 11:52:45 ON 20 DEC 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'MEDLINE' ENTERED AT 11:52:45 ON 20 DEC 2004

FILE 'CAPLUS' ENTERED AT 11:52:45 ON 20 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:52:45 ON 20 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 11:52:45 ON 20 DEC 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s detect? (5a) polymorphism?
   4 FILES SEARCHED...
L1       24950 DETECT? (5A) POLYMORPHISM?

=> s l1 and probes
L2        7862 L1 AND PROBES

=> s l2 and hybridization
L3        6056 L2 AND HYBRIDIZATION

=> s l3 and intensities
L4         671 L3 AND INTENSITIES

=> s l4 and upstream
L5         354 L4 AND UPSTREAM

=> s l5 and downstream
L6         307 L5 AND DOWNSTREAM

=> s l6 and third (4a) probes
L7          42 L6 AND THIRD (4A) PROBES

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8           42 DUP REM L7 (0 DUPLICATES REMOVED)

=> d l8 bib abs 1-42

L8   ANSWER 1 OF 42  USPATFULL on STN
AN     2004:299170  USPATFULL
TI     Polymorphic markers of prostate carcinoma tumor antigen -1(PCTA-1)
IN     Blumenfeld, Marta, Paris, FRANCE
       Bougueleret, Lydie, Vanves, FRANCE
       Chumakov, Ilya, Vaux-le-Penil, FRANCE
PI     US 2004235037      A1   20041125
```

AI US 2004-856888 A1 20040527 (10)
RLI Division of Ser. No. US 1999-326402, filed on 4 Jun 1999, GRANTED, Pat. No. US 6759192
PRAI US 1998-88187P 19980605 (60)
US 1998-102324P 19980928 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 9908
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns the geNo.mic sequence and cDNA sequences of the PCTA-1 gene. The invention also concerns biallelic markers of the PCTA-1 gene and the association established between these markers and prostate cancer. The invention provides means to determine the predisposition of individuals to prostate cancer as well as means for the diagNo.sis of prostate cancer and for the progNo.sis/detection of an eventual treatment response to agents acting against prostate cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 42 USPATFULL on STN
AN 2004:280265 USPATFULL
TI Oligonucleotides useful for detecting and analyzing nucleic acids of interest
IN Kauppinen, Sakari, Smorum, DENMARK
Alsbo, Carsten, Koge, DENMARK
Nielsen, Peter S., Birkerod, DENMARK
Jeffares, Daniel C., Kobenhavn N, DENMARK
Mourier, Tobias, Kobenhavn N, DENMARK
Mork, Soren, Valby, DENMARK
Arctander, Peter, Askeby, DENMARK
Tommerup, Niels, Albertslund, DENMARK
Tolstrup, Niels, Klampenborg, DENMARK
Vissing, Henrik, Virum, DENMARK
PI US 2004219565 A1 20041104
AI US 2003-690487 A1 20031021 (10)
PRAI DK 2003-752 20030519
US 2002-420278P 20021021 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 184
ECL Exemplary Claim: 1
DRWN 48 Drawing Page(s)
LN.CNT 14594
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features improved nucleic acids and methods for expression profiling of mRNAs, identifying and profiling of particular mRNA splice variants, and detecting mutations, deletions, or duplications of particular exons or other splice variants, e.g., alterations associated with a disease such as cancer, in a nucleic acid sample, e.g., a biological sample or a patient sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 42 USPATFULL on STN
AN 2004:210700 USPATFULL
TI PG-3 and biallelic markers thereof

IN Barry, Caroline, Les Ulis Cheptainville, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
PI US 2004163137 A1 20040819
AI US 2004-468582 A1 20040315 (10)
WO 2001-IB274 20010220
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 14069
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns the genomic sequence and cDNA sequences of the PG-3 gene. The invention also concerns biallelic markers of the PG-3 gene. The invention also concerns polypeptides encoded by the PG-3 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 42 USPATFULL on STN
AN 2004:120091 USPATFULL
TI Schizophrenia-related voltage-gated ion channel gene and protein
IN Cohen, Daniel, Paris, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Simon, Anne-Marie, Paris, FRANCE
Abderrahim, Hadi, Charenton le Pont, FRANCE
PI US 2004091497 A1 20040513
AI US 2003-433580 A1 20031110 (10)
WO 2001-IB2798 20011204
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 15303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns the genomic DNA, cDNA, and polypeptide sequences of CanIon, a voltage gated ion channel protein. The invention also concerns biallelic markers of the CanIon gene. The CanIon gene may be used as a biological target for the treatment and diagnosis of schizophrenia, bipolar disorder, and other diseases and conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 42 USPATFULL on STN
AN 2004:63747 USPATFULL
TI Obesity associated biallelic marker maps
IN Cohen, Daniel, Paris, FRANCE
Blumenfeld, Marta, Paris, FRANCE
Chumakov, Ilya, Vaux-le Penil, FRANCE
Abderrahim, Hadi, Charenton le Pont, FRANCE
Bihain, Bernard, Cancale, FRANCE
PI US 2004048265 A1 20040311
AI US 2003-333429 A1 20030922 (10)
WO 2001-IB1477 20010628
DT Utility
FS APPLICATION

LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 11255
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to genomic maps comprising biallelic markers, new biallelic markers, and methods of using biallelic markers. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides a number of methods utilizing the biallelic markers of the invention including methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 42 USPATFULL on STN
AN 2004:50802 USPATFULL
TI Biallelic markers related to genes involved in drug metabolism
IN Blumenfeld, Marta, Paris, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
Cohen, Annick, Paris, FRANCE
PI US 2004038231 A1 20040226
AI US 2002-294934 A1 20021114 (10)
RLI Division of Ser. No. US 2000-671317, filed on 27 Sep 2000, GRANTED, Pat. No. US 6528260 Continuation-in-part of Ser. No. US 2000-536178, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 2000-IB403, filed on 24 Mar 2000, UNKNOWN
PRAI US 1999-126269P 19990325 (60)
US 1999-131961P 19990430 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10728
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides polynucleotides including biallelic markers derived from genes involved in the biotransformation of xenobiotics such as drugs and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 42 USPATFULL on STN
AN 2004:31718 USPATFULL
TI Methods and compositions for inhibiting neoplastic cell growth
IN Yen, Frances, San Diego, CA, UNITED STATES
Denison, Blake, San Diego, CA, UNITED STATES

Duclert, Aymeric, Saint-Maur, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Clusel, Catherine, Montreuil-sous-Bois, FRANCE
Dumas Milne-Edwards, Jean-Baptiste, Paris, FRANCE
Bihain, Bernard, Encinitas, CA, UNITED STATES
Bour, Barbara, San Diego, CA, UNITED STATES
Ebbets-Reed, Dana, Encinitas, CA, UNITED STATES
Salter-Cid, Luisa, San Diego, CA, UNITED STATES
PA GENSET, S.A., Paris, FRANCE (U.S. corporation)
PI US 2004023860 A1 20040205
US 2004248780 A9 20041209
AI US 2002-121034 A1 20020411 (10)
RLI Division of Ser. No. US 2000-750580, filed on 28 Dec 2000, GRANTED, Pat. No. US 6455280 Continuation-in-part of Ser. No. US 2000-599362, filed on 21 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-469099, filed on 21 Dec 1999, ABANDONED
PRAI WO 2000-IB101 20000621
WO 1999-IB2058 19991220
US 1998-113686P 19981222 (60)
US 1999-141032P 19990625 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 42 USPATFULL on STN
AN 2004:24652 USPATFULL
TI Detection of nucleic acid reactions on bead arrays
IN Gunderson, Kevin, Encinitas, CA, UNITED STATES
Stuelpnagel, John R., Encinitas, CA, UNITED STATES
Chee, Mark S., Del Mar, CA, UNITED STATES
PI US 2004018491 A1 20040129
AI US 2001-45575 A1 20011026 (10)
PRAI US 2000-244119P 20001026 (60)
DT Utility
FS APPLICATION
LREP David C. Foster, Suite 3400, Four Embarcadero Center, San Francisco, CA, 94111-4187
CLMN Number of Claims: 14
ECL Exemplary Claim: 1

DRWN 38 Drawing Page(s)
LN.CNT 7222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to methods and compositions for the use of microsphere arrays to detect and quantify a number of nucleic acid reactions. The invention finds use in genotyping, i.e. the determination of the sequence of nucleic acids, particularly alterations such as nucleotide substitutions (mismatches) and single nucleotide polymorphisms (SNPs). Similarly, the invention finds use in the detection and quantification of a nucleic acid target using a variety of amplification techniques, including both signal amplification and target amplification. The methods and compositions of the invention can be used in nucleic acid sequencing reactions as well. All applications can include the use of adapter sequences to allow for universal arrays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 42 USPATFULL on STN
AN 2004:7350 USPATFULL
TI Biallelic markers for use in constructing a high density disequilibrium map of the human genome
IN Cohen, Daniel, Neuilly-Sur-Seine, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Blumenfeld, Marta, Paris, FRANCE
PI US 2004005584 A1 20040108
AI US 2003-349143 A1 20030121 (10)
RLI Division of Ser. No. US 1999-422978, filed on 20 Oct 1999, GRANTED, Pat. No. US 6537751 Continuation-in-part of Ser. No. US 1999-298850, filed on 21 Apr 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-IB822, filed on 21 Apr 1999, UNKNOWN
PRAI US 1998-82614P 19980421 (60)
US 1998-109732P 19981123 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 78
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 12734
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to genomic maps comprising biallelic markers, new biallelic markers, and methods of using biallelic markers. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides a number of methods utilizing the biallelic markers of the invention including methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 42 USPATFULL on STN
AN 2004:301954 USPATFULL
TI Nucleic acids encoding human TBC-1 protein and polymorphic markers thereof
IN Blumenfeld, Marta, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Chumakov, Ilya, Vaux-le-Penil, FRANCE
PA Genset S.A., FRANCE (non-U.S. corporation)

PI US 6825004 B1 20041130
WO 2000008209 20000217
AI US 2001-762311 20010625 (9)
WO 1999-IB1444 19990608
20010625 PCT 371 date
PRAI US 1998-95653P 19980807 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Myers, Carla J.
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 30
ECL Exemplary Claim: 23
DRWN 1 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 7107
AB The invention concerns genomic and cDNA sequences of the human TBC-1 Gene. The invention also concerns polypeptides encoded by the TBC-1 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the TBC-1 gene useful in genetic analysis.

L8 ANSWER 11 OF 42 USPATFULL on STN
AN 2004:167979 USPATFULL
TI Polymorphic markers of prostate carcinoma tumor antigen-1(PCTA-1)
IN Blumenfeld, Marta, Paris, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
PA Genset S.A., FRANCE (non-U.S. corporation)
PI US 6759192 B1 20040706
AI US 1999-326402 19990604 (9)
PRAI US 1998-102324P 19980928 (60)
US 1998-88187P 19980605 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Allen, Marianne P.; Assistant Examiner: Mahatan, Channing S.
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 14546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns the geNo.mic sequence and cDNA sequences of the PCTA-1 gene. The invention also concerns biallelic markers of the PCTA-1 gene and the association established between these markers and prostate cancer. The invention provides means to determine the predisposition of individuals to prostate cancer as well as means for the diagNo.sis of prostate cancer and for the progNo.sis/detection of an eventual treatment response to agents acting against prostate cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 42 USPATFULL on STN
AN 2003:324607 USPATFULL
TI Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
IN Blumenfeld, Marta, Paris, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Cohen, Annick, Paris, FRANCE
PI US 2003228582 A1 20031211

PI US 6794143 B2 20040921
AI US 2002-170097 A1 20020610 (10)
RLI Division of Ser. No. US 2000-641638, filed on 16 Aug 2000, GRANTED, Pat. No. US 6432648 Continuation-in-part of Ser. No. US 2000-502330, filed on 11 Feb 2000, ABANDONED Continuation-in-part of Ser. No. WO 2000-IB184, filed on 11 Feb 2000, UNKNOWN Continuation-in-part of Ser. No. US 1999-275267, filed on 23 Mar 1999, ABANDONED
PRAI US 1999-133200P 19990507 (60)
US 1999-119917P 19990212 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 11720
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides polynucleotides including biallelic markers derived from genes involved in arachidonic acid metabolism and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 42 USPATFULL on STN
AN 2003:312153 USPATFULL
TI Schizophrenia associated genes, proteins and biallelic markers
IN Cohen, Daniel, Paris, FRANCE
Blumenfeld, Marta, Paris, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Bihain, Bernard, Cancale, FRANCE
Essioux, Laurent, Paris, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003219750 A1 20031127
AI US 2002-147603 A1 20020516 (10)
RLI Division of Ser. No. US 2000-539333, filed on 30 Mar 2000, GRANTED, Pat. No. US 6476208 Continuation-in-part of Ser. No. US 1999-416384, filed on 12 Oct 1999, PENDING
PRAI US 1999-126903P 19990330 (60)
US 1999-131971P 19990430 (60)
US 1999-132065P 19990430 (60)
US 1999-143928P 19990714 (60)
US 1999-145915P 19990727 (60)
US 1999-146453P 19990729 (60)
US 1999-146452P 19990729 (60)
US 1999-162288P 19991028 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 12578
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 42 USPATFULL on STN
AN 2003:306387 USPATFULL
TI Detection of nucleic acid reactions on bead arrays
IN Gunderson, Kevin, Encinitas, CA, UNITED STATES
Stuelpnagel, John R., Encinitas, CA, UNITED STATES
Chee, Mark S., Del Mar, CA, UNITED STATES
PI US 2003215821 A1 20031120
AI US 2002-264571 A1 20021004 (10)
RLI Continuation of Ser. No. US 2000-553993, filed on 20 Apr 2000, PENDING
PRAI US 1999-135123P 19990520 (60)
US 1999-160917P 19991022 (60)
US 1999-135051P 19990520 (60)
US 1999-161148P 19991022 (60)
US 1999-130089P 19990420 (60)
US 1999-160027P 19991018 (60)
US 1999-135053P 19990520 (60)
DT Utility
FS APPLICATION
LREP Vicki G. Norton, Esq., BROBECK, PHLEGER & HARRISON LLP, 12390 El Camino Real, San Diego, CA, 92130
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 6549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to methods and compositions for the use of microsphere arrays to detect and quantify a number of nucleic acid reactions. The invention finds use in genotyping, i.e. the determination of the sequence of nucleic acids, particularly alterations such as nucleotide substitutions (mismatches) and single nucleotide polymorphisms (SNPs). Similarly, the invention finds use in the detection and quantification of a nucleic acid target using a variety of amplification techniques, including both signal amplification and target amplification. The methods and compositions of the invention can be used in nucleic acid sequencing reactions as well. All applications can include the use of adapter sequences to allow for universal arrays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 42 USPATFULL on STN
AN 2003:294280 USPATFULL
TI Detection of nucleic acid reactions on bead arrays
IN Gunderson, Kevin, Encinitas, CA, UNITED STATES
Stuelpnagel, John R., Encinitas, CA, UNITED STATES
Chee, Mark S., Del Mar, CA, UNITED STATES
PI US 2003207295 A1 20031106
AI US 2002-264574 A1 20021004 (10)
RLI Continuation of Ser. No. US 2000-553993, filed on 20 Apr 2000, PENDING
PRAI US 1999-135123P 19990520 (60)

PRAI US 1999-160917P 19991022 (60)
US 1999-135051P 19990520 (60)
US 1999-161148P 19991022 (60)
US 1999-130089P 19990420 (60)
US 1999-160027P 19991018 (60)
US 1999-135053P 19990520 (60)
DT Utility
FS APPLICATION
LREP Vicki G. Norton, Esq., BROBECK, PHLEGER & HARRISON LLP, 12390 El Camino Real, San Diego, CA, 92130
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 6546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to methods and compositions for the use of microsphere arrays to detect and quantify a number of nucleic acid reactions. The invention finds use in genotyping, i.e. the determination of the sequence of nucleic acids, particularly alterations such as nucleotide substitutions (mismatches) and single nucleotide polymorphisms (SNPs). Similarly, the invention finds use in the detection and quantification of a nucleic acid target using a variety of amplification techniques, including both signal amplification and target amplification. The methods and compositions of the invention can be used in nucleic acid sequencing reactions as well. All applications can include the use of adapter sequences to allow for universal arrays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 42 USPATFULL on STN
AN 2003:271033 USPATFULL
TI Polymorphic markers of the LSR gene
IN Blumenfeld, Marta, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Bihain, Bernard, Cancale, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003190636 A1 20031009
AI US 2002-214684 A1 20020807 (10)
RLI Division of Ser. No. US 2000-499522, filed on 10 Feb 2000, GRANTED, Pat. No. US 6479238
PRAI US 1999-119592P 19990210 (60)
US 1999-144784P 19990720 (60)
DT Utility
FS APPLICATION
LREP Frank C. Eisenschenk, Ph.D., SALIWANCHIK LLOYD & SALIWANCHIK, Suite A-1, 2421 N.W. 41st Street, Gainesville, FL, 32606-6669
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 7569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel LSR genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the LSR locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 42 USPATFULL on STN
AN 2003:244238 USPATFULL
TI Nucleic acid encoding a retinoblastoma binding protein (RBP-7) and polymorphic markers associated with said nucleic acid
IN Bougueleret, Lydie, Petit Lancy, SWITZERLAND
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003170647 A1 20030911
AI US 2002-126704 A1 20020420 (10)
RLI Division of Ser. No. US 1999-345882, filed on 30 Jun 1999, GRANTED, Pat. No. US 6399373
PRAI US 1998-91315P 19980630 (60)
US 1998-111909P 19981210 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 9151
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a polynucleotide comprising open reading frames defining a coding region encoding a retinoblastoma binding protein (RBP-7) as well as regulatory regions located both at the 5'en d and the 3' end of said coding region. The present invention also pertains to a polynucleotide carrying the natural regulation signals of the RBP-7 gene which is useful in order to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory region. The invention also concerns polypeptides encoded by the coding region of the RBP-7 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention also comprises genetic markers, namely biallelic markers, that are means that may be useful for the diagnosis of diseases related to an alteration in the regulation or in the coding regions of the RBP-7 gene and for the prognosis/diagnosis of an eventual treatment with therapeutic agents, especially agents acting on pathologies involving abnormal cell proliferation and/or abnormal cell differentiation

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 42 USPATFULL on STN
AN 2003:237669 USPATFULL
TI PG-3 and biallelic markers thereof
IN Barry, Caroline, Les Ulis, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
PI US 2003165826 A1 20030904
AI US 2001-790289 A1 20010221 (9)
RLI Continuation-in-part of Ser. No. WO 2000-IB1098, filed on 28 Jul 2000, UNKNOWN
PRAI US 1999-149941P 19990819 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 14935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns the genomic sequence and cDNA sequences of the PG-3 gene. The invention also concerns biallelic markers of the PG-3 gene. The invention also concerns polypeptides encoded by the PG-3 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 42 USPATFULL on STN
AN 2003:194480 USPATFULL
TI **Polymorphism detection**
IN Lipshutz, Robert J., Palo Alto, CA, UNITED STATES
Chee, Mark S., Del Mar, CA, UNITED STATES
Cronin, Maureen T., Los Altos, CA, UNITED STATES
Fodor, Stephen P.A., Palo Alto, CA, UNITED STATES
Hubbell, Earl A., Mountain View, CA, UNITED STATES
Morris, MacDonald S., Altherton, CA, UNITED STATES
Miyada, Charles Garrett, San Jose, CA, UNITED STATES
PA Affymetrix, Inc., Santa Clara, CA, UNITED STATES, 95051 (U.S. corporation)
PI US 2003134291 A1 20030717
AI US 2002-113885 A1 20020328 (10)
RLI Continuation of Ser. No. US 1998-15263, filed on 29 Jan 1998, ABANDONED Division of Ser. No. US 1995-563762, filed on 29 Nov 1995, GRANTED, Pat. No. US 5858659 Division of Ser. No. US 1995-441887, filed on 16 May 1995, GRANTED, Pat. No. US 5837832 Continuation of Ser. No. US 1993-143312, filed on 26 Oct 1993, ABANDONED Continuation-in-part of Ser. No. US 1993-82937, filed on 25 Jun 1993, ABANDONED Continuation-in-part of Ser. No. US 1995-544381, filed on 10 Oct 1995, GRANTED, Pat. No. US 6027880 Continuation-in-part of Ser. No. US 1995-510521, filed on 2 Aug 1995, PENDING Continuation-in-part of Ser. No. WO 1994-US12305, filed on 26 Oct 1994, PENDING Continuation-in-part of Ser. No. US 1994-284064, filed on 2 Aug 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-143312, filed on 26 Oct 1993, ABANDONED
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 758
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention generally provides a rapid efficient method for analyzing polymorphic or biallelic markers, and arrays for carrying out these analyses. In general, the methods of the present invention employ arrays of oligonucleotide **probes** that are complementary to target nucleic acids which correspond to the marker sequences of an individual. The **probes** are typically arranged in detection blocks, each block being capable of discriminating the three genotypes for a given marker, e.g., the heterozygote or either of the two homozygotes. The method allows for rapid, automatable analysis of genetic linkage to even complex polygenic traits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 42 USPATFULL on STN
AN 2003:159269 USPATFULL
TI Nucleic acid encoding a retinoblastoma binding protein (RBP-7) and polymorphic markers associated with said nucleic acid
IN Bougueleret, Lydie, Petit Lancy, SWITZERLAND

PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003108882 A1 20030612
AI US 2002-71179 A1 20020319 (10)
RLI Division of Ser. No. US 1999-345882, filed on 30 Jun 1999, GRANTED, Pat. No. US 6399373
PRAI US 1998-91315P 19980630 (60)
US 1998-111909P 19981210 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., Genset Corp., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 9173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a polynucleotide comprising open reading frames defining a coding region encoding a retinoblastoma binding protein (RBP-7) as well as regulatory regions located both at the 5' end and the 3' end of said coding region. The present invention also pertains to a polynucleotide carrying the natural regulation signals of the RBP-7 gene which is useful in order to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory region. The invention also concerns polypeptides encoded by the coding region of the RBP-7 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention also comprises genetic markers, namely biallelic markers, that are means that may be useful for the diagnosis of diseases related to an alteration in the regulation or in the coding regions of the RBP-7 gene and for the prognosis/diagnosis of an eventual treatment with therapeutic agents, especially agents acting on pathologies involving abnormal cell proliferation and/or abnormal cell differentiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 42 USPATFULL on STN
AN 2003:146220 USPATFULL
TI Nucleic acids encoding human CIDE-B protein and polymorphic markers thereof
IN Bougueleret, Lydie, Petit Lancy, SWITZERLAND
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003099965 A1 20030529
AI US 2002-117894 A1 20020620 (10)
RLI Division of Ser. No. US 2001-807166, filed on 10 Sep 2001, GRANTED, Pat. No. US 6472517
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3905
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a purified or isolated polynucleotide encoding human CIDE B protein, the regulatory nucleic acids contained therein, polymorphic markers thereof, and the resulting encoded protein, as well as to methods and kits for detecting this polynucleotide and this protein. The present invention also pertains to a polynucleotide carrying the natural regulatory regions of the CIDE B gene which is

useful, for example, to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory regions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 42 USPATFULL on STN
AN 2003:45471 USPATFULL
TI Apolipoprotein A-IV-related protein: polypeptide, polynucleotide sequences and biallelic markers thereof
IN Yen-Potin, Frances, San Diego, CA, UNITED STATES
Denison, Blake, San Diego, CA, UNITED STATES
Milne Edwards, Jean Baptiste Dumas, Paris, FRANCE
Bihain, Bernard, Carlsbad, CA, UNITED STATES
Bour, Barbara, San Diego, CA, UNITED STATES
Duclert, Aymeric, Saint-Maur, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
PI US 2003032783 A1 20030213
AI US 2001-842364 A1 20010425 (9)
RLI Continuation of Ser. No. US 2000-599362, filed on 21 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-469099, filed on 21 Dec 1999, ABANDONED
PRAI WO 1999-IB2058 19991220
US 1998-113686P 19981222 (60)
US 1999-141032P 19990625 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 10688
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides the genomic sequence of AA4RP, AA4RP cDNAs and AA4RP polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the AA4RP gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also relates to diagnostic methods for determining whether an individual is at risk of developing a lipid metabolism related disorder and/or a liver related disorder, or whether said individual suffers from a lipid metabolism related disorder and/or a liver related disorder as a result of a polymorphism in the AA4RP gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 42 USPATFULL on STN
AN 2003:115714 USPATFULL
TI Schizophrenia associated gene, proteins and biallelic markers
IN Cohen, Daniel, Neuilly-sur-Seine, FRANCE
Blumenfeld, Marta, Paris, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Essioux, Laurent, Paris, FRANCE
PA Genset S.A., FRANCE (non-U.S. corporation)
PI US 6555316 B1 20030429
AI US 2000-679409 20001003 (9)

RLI Continuation-in-part of Ser. No. US 2000-539333, filed on 30 Mar 2000, now patented, Pat. No. US 6476208 Continuation-in-part of Ser. No. US 1999-416384, filed on 12 Oct 1999
PRAI US 1999-168088P 19991130 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Fredman, Jeffrey
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 9055
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns the human g35030 gene, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the g35030 gene and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 42 USPATFULL on STN
AN 2003:81578 USPATFULL
TI Biallelic markers for use in constructing a high density disequilibrium map of the human genome
IN Cohen, Daniel, Neuilly-sur-Seine, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Blumenfeld, Marta, Paris, FRANCE
PA Genset S.A., FRANCE (non-U.S. corporation)
PI US 6537751 B1 20030325
AI US 1999-422978 19991020 (9)
RLI Continuation-in-part of Ser. No. US 1999-298850, filed on 21 Apr 1999, now abandoned Continuation-in-part of Ser. No. WO 1999-IB822, filed on 21 Apr 1999
PRAI US 1998-109732P 19981123 (60)
US 1998-82614P 19980421 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Goldberg, Jeanine
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 10067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to genomic maps comprising biallelic markers, new biallelic markers, and methods of using biallelic markers. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides a number of methods utilizing the biallelic markers of the invention including methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 42 USPATFULL on STN
AN 2003:60071 USPATFULL
TI Biallelic markers related to genes involved in drug metabolism
IN Blumenfeld, Marta, Paris, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
Cohen, Annick, Paris, FRANCE
PA Genset, S.A., FRANCE (non-U.S. corporation)
PI US 6528260 B1 20030304
AI US 2000-671317 20000927 (9)
RLI Continuation-in-part of Ser. No. US 2000-536178, filed on 23 Mar 2000
PRAI US 1999-126269P 19990325 (60)
US 1999-131961P 19990430 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Woodward, Michael P.; Assistant Examiner: Clow, Lou A
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 8385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides polynucleotides including biallelic markers derived from genes involved in the biotransformation of xenobiotics such as drugs and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 42 USPATFULL on STN
AN 2002:314664 USPATFULL
TI Detection of nucleic acid amplification reactions using bead arrays
IN Chee, Mark S., Del Mar, CA, UNITED STATES
Gunderson, Kevin, Encinitas, CA, UNITED STATES
PA Illumina, Inc. (2)
PI US 2002177141 A1 20021128
AI US 2001-21906 A1 20011212 (10)
RLI Continuation of Ser. No. US 2000-517945, filed on 3 Mar 2000, GRANTED, Pat. No. US 6355431
PRAI US 1999-161148P 19991022 (60)
US 1999-135051P 19990520 (60)
US 1999-160027P 19991018 (60)
US 1999-130089P 19990420 (60)
US 1999-135053P 19990520 (60)
US 1999-135123P 19990520 (60)
US 1999-160927P 19991022 (60)
US 1999-160917P 19991022 (60)
DT Utility
FS APPLICATION
LREP FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP, Suite 3400, Four Embarcadero Center, San Francisco, CA, 94111-4187
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 3743
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions and methods for detecting and quantifying a target nucleic acid using a variety of both signal amplification and target amplification techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 42 USPATFULL on STN
AN 2002:295295 USPATFULL
TI Prostate cancer gene
IN Cohen, Daniel, Neuilley sur Seine, FRANCE
Blumenfeld, Marta, Paris, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
PI US 2002165345 A1 20021107
AI US 2001-853526 A1 20010827 (9)
RLI Division of Ser. No. US 1999-338907, filed on 23 Jun 1999, PATENTED Continuation-in-part of Ser. No. US 1998-218207, filed on 22 Dec 1998, PATENTED Continuation-in-part of Ser. No. US 1997-996306, filed on 22 Dec 1997, PATENTED
PRAI US 1998-99658P 19980909 (60)
DT Utility
FS APPLICATION
LREP Frank C. Eisenchenk, Ph.D., Saliwanchik, Lloyd & Saliwanchik, Suite A-1, 2421 N.W. 41st Street, Gainesville, FL, 32606-6669
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 8016
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer. The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate cancer as a result of a mutation in the PG1 gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 42 USPATFULL on STN
AN 2002:259377 USPATFULL
TI Methods and compositions for inhibiting neoplastic cells growth
IN Yen, Frances, San Diego, CA, UNITED STATES
Denison, Blake, San Diego, CA, UNITED STATES
Bour, Barbara, San Diego, CA, UNITED STATES
Bihain, Bernard, Encinitas, CA, UNITED STATES
Edwards, Jean-Baptiste Dumas Milne, Paris, FRANCE
Duclert, Aymeric, Saint-Maur, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Ebbets-Reed, Dana, Encinitas, CA, UNITED STATES
Salter-Cid, Luisa, San Diego, CA, UNITED STATES
PI US 2002142949 A1 20021003
US 2004204349 A9 20041014
AI US 2000-751877 A1 20001228 (9)
DT Utility
FS APPLICATION

LREP GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY RD, SAN DIEGO, CA, 92121
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 11080
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 42 USPATFULL on STN
AN 2002:221321 USPATFULL
TI Prostate cancer gene
IN Cohen, Daniel, Nevilly Sur Seine, FRANCE
Blumenfeld, Marta, Paris, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
PI US 2002119460 A1 20020829
AI US 2001-901484 A1 20010709 (9)
RLI Division of Ser. No. US 1999-338907, filed on 23 Jun 1999, GRANTED, Pat. No. US 6265546 Continuation-in-part of Ser. No. US 1998-218207, filed on 22 Dec 1998, GRANTED, Pat. No. US 6346381 Continuation-in-part of Ser. No. US 1997-996306, filed on 22 Dec 1997, GRANTED, Pat. No. US 5945522 Continuation-in-part of Ser. No. US 2001-853526, filed on 27 Aug 2001, PENDING
PRAI US 1998-99658P 19980909 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 8051
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer. The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate cancer as a result of a mutation in the

PG1 gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 42 USPATFULL on STN
AN 2002:185584 USPATFULL
TI **Polymorphism detection**
IN Lipshutz, Robert J., Palo Alto, CA, UNITED STATES
Sapolsky, Ronald, Mountain View, CA, UNITED STATES
Ghandour, Ghassan, Atherton, CA, UNITED STATES
PI US 2002098496 A1 20020725
US 6586186 B2 20030701
AI US 2001-939119 A1 20010824 (9)
RLI Continuation of Ser. No. US 1997-853370, filed on 8 May 1997, GRANTED, Pat. No. US 6300063 Continuation-in-part of Ser. No. US 1995-563762, filed on 29 Nov 1995, GRANTED, Pat. No. US 5858659
PRAI US 1996-17260P 19960510 (60)
DT Utility
FS APPLICATION
LREP RITTER, LANG & KAPLAN, 12930 SARATOGA AE. SUITE D1, SARATOGA, CA, 95070
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention generally provides a rapid efficient method for analyzing polymorphic or biallelic markers, and arrays for carrying out these analyses. In general, the methods of the present invention employ arrays of oligonucleotide **probes** that are complementary to target nucleic acids which correspond to the marker sequences of an individual. The **probes** are typically arranged in detection blocks, each block being capable of discriminating the three genotypes for a given marker, e.g., the heterozygote or either of the two homozygotes. The method allows for rapid, automatable analysis of genetic linkage to even complex polygenic traits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 42 USPATFULL on STN
AN 2002:156985 USPATFULL
TI GENES, PROTEINS AND BIALLELIC MARKERS RELATED TO CENTRAL NERVOUS SYSTEM DISEASE
IN BLUMENFELD, MARTA, PARIS, FRANCE
BOUGUELERET, LYDIE, VANVES, FRANCE
CHUMAKOV, ILYA, VAUX-LE-PENIL, FRANCE
ESSIOUX, LAURENT, PARIS, FRANCE
COHEN, DANIEL, NEUILLY-SUR-SEINE, FRANCE
PI US 2002081584 A1 20020627
AI US 1999-416384 A1 19991012 (9)
PRAI US 1998-103955P 19981013 (60)
US 1998-106457P 19981030 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 10828
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns genes, polymorphisms and polypeptides related to central nervous systems disease. Included are the G713 gene, the G713

protein and G713 biallelic markers, as well as biallelic markers located on the human chromosome 13q31-q33 locus, and the association established between these biallelic markers and schizophrenia. The invention also provides means to determine the predisposition of individuals to schizophrenia as well as means for the diagnosis of this disease and for the prognosis and detection of an eventual treatment response to therapeutic agents acting against schizophrenia

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 42 USPATFULL on STN
AN 2002:297416 USPATFULL
TI Polymorphic markers of the LSR gene
IN Blumenfeld, Marta, Paris, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
Bihain, Bernard, Encinitas, CA, United States
PI US 6479238 B1 20021112
AI US 2000-499522 20000210 (9)
PRAI US 1999-119592P 19990210 (60)
US 1999-144784P 19990720 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ketter, James
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 7336
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel LSR genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the LSR locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 33 OF 42 USPATFULL on STN
AN 2002:291075 USPATFULL
TI Schizophrenia associated genes, proteins and biallelic markers
IN Cohen, Daniel, Neuilly-Sue-Seine, FRANCE
Blumenfeld, Marta, Paris, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
Bihain, Bernard, Encinitas, CA, United States
Essioux, Laurent, Paris, FRANCE
PA Genset, FRANCE (non-U.S. corporation)
PI US 6476208 B1 20021105
AI US 2000-539333 20000330 (9)
RLI Continuation-in-part of Ser. No. US 1999-416384, filed on 12 Oct 1999
PRAI US 1999-126903P 19990330 (60)
US 1999-131971P 19990430 (60)
US 1999-132065P 19990430 (60)
US 1999-143928P 19990714 (60)
US 1999-145915P 19990727 (60)
US 1999-146453P 19990729 (60)
US 1999-146452P 19990729 (60)
US 1999-162288P 19991028 (60)
DT Utility

FS GRANTED
EXNAM Primary Examiner: Fredman, Jeffrey
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 10859
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 34 OF 42 USPATFULL on STN
AN 2002:283364 USPATFULL
TI Nucleic acids encoding human CIDE-B protein and polymorphic markers thereof
IN Bougueleret, Lydie, Petit Lancy, SWITZERLAND
PA Genset S.A., Paris, FRANCE (non-U.S. corporation)
PI US 6472517 B1 20021029
WO 2000021984 20000420
AI US 2001-807166 20010910 (9)
WO 1999-IB8901702 19991008
PRAI US 1998-103729P 19981009 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Myers, Carla J.
LREP Lucas, John, Johns, Carol
CLMN Number of Claims: 68
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 4016
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a purified or isolated polynucleotide encoding human CIDE B protein, the regulatory nucleic acids contained therein, polymorphic markers thereof, and the resulting encoded protein, as well as to methods and kits for detecting this polynucleotide and this protein. The present invention also pertains to a polynucleotide carrying the natural regulatory regions of the CIDE B gene which is useful, for example, to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory regions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 35 OF 42 USPATFULL on STN
AN 2002:246560 USPATFULL
TI Methods and compositions for inhibiting neoplastic cell growth
IN Edwards, Jean-Baptiste Dumas Milne, Paris, FRANCE
Duclert, Aymeric, Saint-Maur, FRANCE
Bougueleret, Lydie, PetitLancy, SWITZERLAND
Clusel, Catherine, Montreuil-sous-Bois, FRANCE
PA Genset S.A., Paris, FRANCE (non-U.S. corporation)
PI US 6455280 B1 20020924

AI US 2000-750580 20001228 (9)
RLI Continuation-in-part of Ser. No. US 2000-599362, filed on 21 Jun 2000
Continuation-in-part of Ser. No. WO 2000-IB1011, filed on 21 Jun 2000
Continuation-in-part of Ser. No. US 1999-469099, filed on 21 Dec 1999
Continuation-in-part of Ser. No. WO 1999-IB2058, filed on 20 Dec 1999
PRAI US 1999-141032P 19990625 (60)
US 1998-113686P 19981222 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bansal, Geetha P.; Assistant Examiner: Davis, Natalie
LREP Lucas, John M., Follette, Peter, Voellmy, Lukas R.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 10937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 36 OF 42 USPATFULL on STN
AN 2002:201845 USPATFULL
TI Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
IN Blumenfeld, Marta, Paris, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Cohen, Annick, Paris, FRANCE
PA Genset, FRANCE (non-U.S. corporation)
PI US 6432648 B1 20020813
AI US 2000-641638 20000816 (9)
RLI Continuation-in-part of Ser. No. US 502330, now abandoned
Continuation-in-part of Ser. No. US 1999-275267, filed on 23 Mar 1999, now abandoned
PRAI US 1999-133200P 19990507 (60)
US 1999-119917P 19990212 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Brusca, John S.
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 9217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides polynucleotides including biallelic markers derived from genes involved in arachidonic acid metabolism and from genomic regions flanking those genes. Primers hybridizing to regions

flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 37 OF 42 USPATFULL on STN
AN 2002:129784 USPATFULL
TI Nucleic acid encoding a retinoblastoma binding protein (RBP-7) and polymorphic markers associated with said nucleic acid
IN Bougueleret, Lydie, Vanves, FRANCE
PA Genset, FRANCE (non-U.S. corporation)
PI US 6399373 B1 20020604
AI US 1999-345882 19990630 (9)
PRAI US 1998-91315P 19980630 (60)
US 1998-111909P 19981210 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Yucel, Remy; Assistant Examiner: Katcheves, Konstantina
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 9924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a polynucleotide comprising open reading frames defining a coding region encoding a retinoblastoma binding protein (RBP-7) as well as regulatory regions located both at the 5' end and the 3' end of said coding region. The present invention also pertains to a polynucleotide carrying the natural regulation signals of the RBP-7 gene which is useful in order to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory region. The invention also concerns polypeptides encoded by the coding region of the RBP-7 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention also comprises genetic markers, namely biallelic markers, that are means that may be useful for the diagnosis of diseases related to an alteration in the regulation or in the coding regions of the RBP-7 gene and for the prognosis/diagnosis of an eventual treatment with therapeutic agents, especially agents acting on pathologies involving abnormal cell proliferation and/or abnormal cell differentiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 38 OF 42 USPATFULL on STN
AN 2002:50784 USPATFULL
TI Detection of nucleic acid amplification reactions using bead arrays
IN Chee, Mark S., Del Mar, CA, United States
Gunderson, Kevin, Encinitas, CA, United States
PA Illumina, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6355431 B1 20020312
AI US 2000-517945 20000303 (9)
PRAI US 1999-161148P 19991022 (60)
US 1999-135051P 19990520 (60)
US 1999-160927P 19991022 (60)
US 1999-130089P 19990420 (60)

US 1999-135053P 19990520 (60)
US 1999-160917P 19991022 (60)
US 1999-135123P 19990520 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Horlick, Kenneth R.; Assistant Examiner: Strzelecka, Teresa
LREP Silva, Robin M., Flehr Hohbach Test Albritton & Herbert LLP
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 3818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compositions and methods for detecting and quantifying a target nucleic acid using a variety of both signal amplification and target amplification techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 39 OF 42 USPATFULL on STN
AN 2002:29243 USPATFULL
TI Prostate cancer gene
IN Cohen, Daniel, Fontenay-sous-bois, FRANCE
Blumenfeld, Marta, Paris, FRANCE
Chumakov, Ilya, Vaux-le-Penil, FRANCE
Bougueleret, Lydie, Vanves, FRANCE
PA Genset, FRANCE (non-U.S. corporation)
PI US 6346381 B1 20020212
AI US 1998-218207 19981222 (9)
RLI Continuation-in-part of Ser. No. US 1997-996306, filed on 22 Dec 1997, now patented, Pat. No. US 5945522
PRAI US 1998-99658P 19980909 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Fredman, Jeffrey
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 17612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer. The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate cancer as a result of a mutation in the PG1 gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 40 OF 42 USPATFULL on STN
AN 2001:173324 USPATFULL
TI **Polymorphism detection**
IN Lipshutz, Robert J., Palo Alto, CA, United States
Sapolsky, Ronald, Mountain View, CA, United States

Ghandour, Ghassan, Atherton, CA, United States
PA Affymetrix, Inc., Santa Clara, CA, United States (U.S. corporation)
PI US 6300063 B1 20011009
AI US 1997-853370 19970508 (8)
RLI Continuation-in-part of Ser. No. US 1995-563762, filed on 29 Nov 1995
PRAI US 1996-17260P 19960510 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Riley, Jezia
LREP Ritter, Lang & Kaplan LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 1044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention generally provides a rapid efficient method for analyzing polymorphic or biallelic markers, and arrays for carrying out these analyses. In general, the methods of the present invention employ arrays of oligonucleotide **probes** that are complementary to target nucleic acids which correspond to the marker sequences of an individual. The **probes** are typically arranged in detection blocks, each block being capable of discriminating the three genotypes for a given marker, e.g., the heterozygote or either of the two homozygotes. The method allows for rapid, automatable analysis of genetic linkage to even complex polygenic traits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 41 OF 42 USPATFULL on STN
AN 2001:117151 USPATFULL
TI Prostate cancer gene
IN Cohen, Daniel, Neuilly sur Seine, France
Blumenfeld, Marta, Paris, France
Chumakov, Ilya, Vaux-le-Penil, France
Bougueleret, Lydie, Vanves, France
PA Genset, France (non-U.S. corporation)
PI US 6265546 B1 20010724
AI US 1999-338907 19990623 (9)
RLI Continuation-in-part of Ser. No. US 1998-218207, filed on 22 Dec 1998
Continuation-in-part of Ser. No. US 1997-996306, filed on 22 Dec 1997, now patented, Pat. No. US 5945522
PRAI US 1998-99658P 19980909 (60)
US 1998-107986P 19981110 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Robinson, Patricia
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 7782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer.

The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate cancer as a result of a mutation in the PG1 gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 42 OF 42 USPATFULL on STN
AN 1999:4327 USPATFULL
TI **Polymorphism detection**
IN Sapolsky, Ronald J., Mountain View, CA, United States
Lipshutz, Robert J., Palo Alto, CA, United States
PA Affymetrix, Inc., Santa Clara, CA, United States (U.S. corporation)
PI US 5858659 19990112
AI US 1995-563762 19951129 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Marschel, Ardin H.; Assistant Examiner: Riley, Jezia
LREP Townsend & Townsend & Crew LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention generally provides a rapid efficient method for analyzing polymorphic or biallelic markers, and arrays for carrying out these analyses. In general, the methods of the present invention employ arrays of oligonucleotide **probes** that are complementary to target nucleic acids which correspond to the marker sequences of an individual. The **probes** are typically arranged in detection blocks, each block being capable of discriminating the three genotypes for a given marker, e.g., the heterozygote or either of the two homozygotes. The method allows for rapid, automatable analysis of genetic linkage to even complex polygenic traits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>